ESMO

Velcade and Rituxan Help Improve Responses in Marginal Zone Lymphoma

November 24th 2023, 2:00pm

Article

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial.

Dato-DXd Led To Antitumor Activity in Some Patients With Pretreated NSCLC

November 23rd 2023, 3:00pm

Article

Datopotamab deruxtecan elicited encouraging responses in patients with heavily pretreated non–small cell lung cancer harboring actionable genomic alterations.

Welireg Plus Cabometyx Shows Anti-Tumor Activity in Kidney Cancer Type

November 22nd 2023, 11:00pm

Article

The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.

Cancer Vaccine Plus Keytruda Improves Survival Without Relapse in Resected Melanoma

November 7th 2023, 2:00pm

Article

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

Trodelvy May Provide Benefits in Extensive-Stage Small Cell Lung Cancer

November 5th 2023, 10:00pm

Article

Patients with extensive-stage small cell lung cancer responded well to the treatment of Trodelvy, according to preliminary results from a phase 2 trial.

Lifileucel Is Efficacious in Advanced Mucosal Melanoma

October 30th 2023, 10:00pm

Article

A phase 2 study evaluated meaningful activity from lifileucel for patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors.

Cancer Data from European Conference May Lead to FDA Approvals

October 30th 2023, 2:00pm

Podcast

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Jemperli Plus Chemo Continues to Demonstrate Strong Outcomes in Advanced NSCLC

October 29th 2023, 4:00pm

Article

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Tecentriq and Zejula Plus Chemo Did Not Offer Better Outcomes in Recurrent Ovarian Cancer

October 29th 2023, 1:00pm

Article

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

Libtayo Shows Survival Benefit In CSCC After Year Follow Up

October 28th 2023, 7:00pm

Article

A recent phase 2 study showed promising survival improvements with neoadjuvant Libtayo in patients with cutaneous squamous cell carcinoma after a year and a half follow up.